Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• T-cell large granular lymphocyte (LGL) leukemia is a rare, indolent cancer.
• Current treatments primarily involve immunosuppression.
• Limited options exist for patients refractory to these therapies.

Observation:

• A 57-year-old male with T-cell LGL leukemia experienced disease relapse after initial immunosuppressive treatment.
• The patient required frequent red blood cell transfusions due to anemia.
• Previous treatments with methotrexate, cyclosporine, and cyclophosphamide showed limited long-term efficacy.

Findings:

• Belinostat treatment led to transfusion independence for over 15 months.
• Bone marrow biopsy showed decreased disease involvement after belinostat therapy.
• This represents the first reported use of belinostat in relapsed/refractory T-cell LGL leukemia.

Implications:

• Belinostat demonstrates potential as an effective therapy for refractory T-cell LGL leukemia.
• This case suggests a new treatment avenue for patients with limited options.
• Further research is warranted to confirm belinostat's efficacy and safety in T-cell LGL leukemia.